Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 105Neoplasms 11Neoplasm Metastasis 11Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Breast Diseases 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2

Interventions

Doxorubicin 2spartalizumab 1selinexor 1ribociclib 1pazopanib 1STA 9090 1Proton Therapy 1Paclitaxel 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disorders of Sex Development × ribociclib × Clear all
NCT03009201 2023-08-16

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 1 Completed
16 enrolled
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Sarcoma, Disorders of Sex Development, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡